Purchase this article with an account.
Vikas Tah, Praveen J. Patel, Fred Chen, Simona Esposti, Adnan Tufail, Lyndon Da Cruz, Pearce A. Keane; Repeatability of Topcon 3DOCT-1000 Optical Coherence Tomography Derived Retinal Thickness Metrics In Neovascular Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2011;52(14):149.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Advances in technology have seen the introduction of spectral-domain optical coherence tomography (SDOCT) imaging as an essential component of the assessment of the patient with neovascular age-related macular degeneration (nAMD) undergoing therapy. However, no studies have investigated the repeatability of automated retinal thickness measurement in these patients to distinguish clinical change from measurement error. The aim of this study was to determine the repeatability of automated Topcon 3DOCT-1000 OCT® retinal thickness measurements in patients with nAMD.
This is a retrospective analysis of OCT images from 91 consecutive patients attending for treatment of nAMD. In line with departmental protocols, two optimized 6 x 6mm raster scan sets were acquired in a single imaging session. Scans were analyzed for the presence of segmentation error and the automated measurement values of retinal thickness and volume were recorded for each subfield. The patients were at different stages of treatment and disease activity. Repeatability was assessed in line with methods outlined by Bland and Altman.
The coefficient of repeatability was 78 µm for the central 1mm subfield. The revised coefficient of repeatability for 43 patients with no central segmentation error was 62 µm. Repeatability values ranged from 112 µm to 56 µm for ETDRS subfields A2 to A9.
The values of repeatability for retinal thickness measures using the Topcon 3DOCT-1000 (an SDOCT device) for nAMD assessment are similar to values obtained using time-domain OCT. The results of this work are important to both clinicians and clinical trial investigators when using quantitative SDOCT metrics to determine retreatment decisions with anti-VEGF agents.
This PDF is available to Subscribers Only